What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

To examine the cumulative incidence of household material hardship and income loss during treatment for acute lymphoblastic leukemia.

December 8, 2025BloodOpen Access

Cumulative incidence of household material hardship and income loss as measures of financial toxicity during pediatric acute lymphoblastic leukemia (ALL) treatment: A report from the DFCI ALL 16-001 Trial

View Full Paper

Ask AI

Bookmark

To examine the cumulative incidence of household material hardship and income loss during treatment for acute lymphoblastic leukemia.
Analyzed data from DFCI ALL 16-001 Trial enrolling children with ALL.
Utilized surveys to assess household material hardship and income loss at multiple time points.
Employed Aalen-Johansen method for estimating cumulative incidence rates.
27% of participants reported household material hardship at baseline.
Cumulative incidence of new hardship was 30% at 24 months.
20% experienced catastrophic income loss by 6 months, increasing to 31% by 24 months.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Analysis reveals significant financial toxicity impacts families during acute lymphoblastic leukemia treatment, indicating urgent need for interventions.

Cite This Study

Zheng et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4c7 https://doi.org/10.1182/blood-2025-710

View Full Paper

Ask AI

Bookmark

Implication

Analysis reveals significant financial toxicity impacts families during acute lymphoblastic leukemia treatment, indicating urgent need for interventions.

Cumulative incidence of household material hardship and income loss as measures of financial toxicity during pediatric acute lymphoblastic leukemia (ALL) treatment: A report from the DFCI ALL 16-001 Trial

Key Points

Discussion

Implication

Cite This Study

Cumulative incidence of household material hardship and income loss as measures of financial toxicity during pediatric acute lymphoblastic leukemia (ALL) treatment: A report from the DFCI ALL 16-001 Trial

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider